VAERS reports by lot

Pfizer COVID-19 lot FL8094: VAERS reports

1,358 VAERS reports list lot FL8094 as a Pfizer COVID-19 vaccine, received between 2021-12-26 and 2024-04-05. Data: VAERS public files through 31 December 2024 (site extract 2026-07-04).

Read this first. VAERS accepts reports from anyone, and a report does not establish that the vaccine caused the event. A lot's report count mostly reflects how many doses it contained, when it was used and who received it; no administered-dose counts are published for this lot, so counts are not rates and cannot rank lots against each other. Lot numbers in VAERS reports are typed by reporters and are sometimes wrong.
1,358
Reports
1%
Marked serious
0
With a death outcome
20
Months with reports

Symptom categories in these reports

A report can mention several categories, so the counts add up to more than the number of reports.

CategoryCount%
General / Systemic (non-local)26625%
Neurological17616%
Gastrointestinal13813%
Cardiac / Cardiovascular12111%
Injection-site / Local reaction828%
Respiratory717%
Dermatological (non-injection-site)636%
Allergic / Anaphylactic596%
Musculoskeletal474%
Psychiatric / Neuropsychiatric182%
Thrombotic / Hematological161%
Autoimmune / Immune-mediated91%
Reproductive / Menstrual10%

Where reports came from

U.S. state of the reporter, where given (top 12).

California155
Texas90
New Jersey69
Colorado62
Massachusetts60
Michigan59
Ohio56
New York50
Maine44
Oregon37
Kentucky32
Washington31

Reports by month received

2021-124
2022-0167
2022-02146
2022-0395
2022-0482
2022-05163
2022-06230
2022-07274
2022-08124
2022-0954
2022-1039
2022-117
2022-1215
2023-0125
2023-022
2023-0315
2023-049
2023-055
2023-071
2024-041

Products recorded with this lot

Manufacturer and product as reported in VAERS. Reports listing the lot under more than one product are counted once.

Related

Source: VAERS public data (CDC/FDA), grouped by manufacturer and lot by the Open Source Medicine Foundation; extract 2026-07-04 16:35 UTC. Not medical advice. Report errors via contact.